
|Articles|April 1, 2016
- Pharmaceutical Executive-04-01-2016
- Volume 36
- Issue 4
Pharmaceutical Executive, April 2016 Issue (PDF)
Click the title above to open the Pharmaceutical Executive April 2016 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 10 years ago
Closing the Gaps in Drug Chain of Custodyalmost 10 years ago
Data Unleashed: Cooperation Among Competitorsalmost 10 years ago
Raising the Stakes On Value-Based Pricingalmost 10 years ago
The Diversity Dearth in Pharmaalmost 10 years ago
Information in Action: A Conversation with Barbara Lopez Kunzalmost 10 years ago
R&D Model Mixes Compassion, Calculationalmost 10 years ago
Pressure Builds to Revamp Off-Label Marketing Rulesalmost 10 years ago
Drug Compounding: A Cause and Cure for High Drug Prices?almost 10 years ago
The Odd Couplealmost 10 years ago
Country Report: EgyptNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly Releases Open Letter Warning of Potential Safety Risks for Compounded Tirzepatide Plus Vitamin B12
2
Agentic AI and the Future of Commercial Excellence in Life Sciences
3
FDA Expands Approval for Arexvy for Adult Patients Aged 18-49
4
What is Shadow AI and How is it Impacting Pharma Companies?
5




